In a move poised to reshape the landscape of infectious disease diagnostics, Utah-based molecular diagnostics firm Co-Diagnostics has officially submitted a Dual 510(k) premarket notification to the US Food and Drug Administration (FDA). This critical filing covers the company’s Co-Dx PCR Flu A/B & RSV multiplex test, designed to run on the innovative Co-Dx PCR Pro instrument.
Concurrent with this submission, the company has filed a CLIA Waiver by Application. If granted, this waiver would serve as a transformative regulatory milestone, authorizing the use of these high-sensitivity molecular tests in decentralized, point-of-care (POC) settings—such as pharmacies, urgent care clinics, and potentially even home environments—rather than restricting them to specialized, centralized clinical laboratories.
Main Facts: A Shift Toward Patient-Centric Diagnostics
The core of Co-Diagnostics’ strategy lies in the democratization of PCR technology. While Polymerase Chain Reaction (PCR) testing is the gold standard for accuracy in detecting viral infections, it has historically been tethered to large, centralized labs due to the complexity of the equipment and the requirement for highly trained personnel.
The Co-Dx PCR platform aims to disrupt this paradigm by pairing the precision of real-time PCR with a significantly lower-cost instrument and consumable model. The platform is supported by a robust, cloud-based infrastructure designed for real-time data aggregation. This allows for not just individual diagnostic results, but also the tracking of localized outbreaks as they emerge, providing public health officials with a granular view of infectious disease spread.
The current submission specifically addresses:
- The Co-Dx PCR Pro Instrument: A compact, user-friendly device engineered for rapid molecular analysis.
- The Flu A/B & RSV Multiplex Test: A diagnostic kit capable of differentiating between influenza A, influenza B, and respiratory syncytial virus from a single upper respiratory sample.
- The CLIA Waiver Request: A strategic regulatory play to bypass the "high complexity" classification of traditional PCR, enabling healthcare providers with minimal laboratory training to operate the device accurately.
Chronology of Development: From Concept to Regulatory Filing
The journey toward this regulatory milestone has been a multi-year endeavor marked by rigorous clinical and analytical validation.
The Path to Submission
- Early Development: Co-Diagnostics focused on the proprietary design of its nucleic acid detection technology, aiming to create a platform that maintains the high-fidelity results of lab-based PCR while simplifying the user interface.
- Analytical Validation (Early 2026): The company executed a massive analytical program involving 27 separate studies. This phase saw the testing of over 10,000 upper respiratory PCR samples to ensure the platform’s reliability, limit of detection, and cross-reactivity profiles.
- Clinical Trials (Mid-2026): The clinical validation phase involved more than 1,400 symptomatic patients across nine geographically diverse clinical sites in the United States. This broad demographic and geographic reach was essential to ensure the test’s efficacy across different viral strains and patient populations.
- Regulatory Milestone (Q3 2026): Consistent with their previously announced roadmap, Co-Diagnostics finalized their data sets and submitted the Dual 510(k) and CLIA Waiver application to the FDA, marking the transition from the R&D phase to the regulatory review phase.
Supporting Data: Rigor in Reproducibility
One of the most significant hurdles for any point-of-care diagnostic device is proving that it performs with equal accuracy in the hands of an untrained operator as it does in a controlled laboratory setting. To satisfy the FDA’s stringent requirements for a CLIA waiver, Co-Diagnostics invested heavily in a multicenter reproducibility study.
The study results were categorical: the Co-Dx PCR platform demonstrated consistent performance across multiple operators, varying environmental conditions, and different test sites. By removing the need for manual sample preparation and automating the data interpretation through the integrated mobile app and cloud system, the company effectively minimized the "human error" variable that often plagues point-of-care testing.
The 10,000-plus test runs included in the analytical program serve as a cornerstone of the company’s submission, providing the FDA with a massive statistical dataset to support the safety and efficacy of the platform. This scale of testing is rarely seen in initial 510(k) submissions, underscoring Co-Diagnostics’ commitment to transparency and clinical confidence.
Official Responses and Strategic Vision
Dwight Egan, CEO of Co-Diagnostics, highlighted the gravity of this submission during a recent press address.
"The submission of this 510(k) premarket notification and CLIA Waiver by Application represents one of the most significant milestones in Co-Diagnostics’ history," Egan stated. He emphasized that this is not merely a product launch, but the realization of years of focused investment into a platform designed to bridge the gap between expensive, inaccessible laboratory diagnostics and the immediate needs of the patient.
"With this submission, we are entering the next phase of our regulatory pathway," Egan added. "Our goal is to bring decentralized PCR diagnostics closer to the patient through a platform designed to improve accessibility, affordability, and ease of use. Furthermore, our cloud-based infrastructure is built to power situational awareness, allowing us to see how infections spread through communities in real-time."
The company’s leadership maintains that by integrating data aggregation into the diagnostic process, they are providing a service that transcends simple medical testing; they are providing a tool for proactive epidemiology.
Implications for the Healthcare Sector
The potential FDA clearance of the Co-Dx PCR system carries profound implications for the medical device industry and public health infrastructure.
1. Decentralization of Molecular Diagnostics
Historically, the speed of diagnosis for respiratory infections has been limited by logistics—the time taken to transport samples to a lab and receive results. By enabling point-of-care PCR, clinicians can receive laboratory-grade results in the time it takes to conduct a standard physical examination. This enables "test-and-treat" workflows, where patients can receive appropriate antiviral medications immediately, significantly improving clinical outcomes.
2. Public Health Surveillance
The platform’s cloud-based connectivity allows for instantaneous reporting of test results to centralized databases. In the event of a regional flu outbreak, health departments could monitor the progression of the virus with unprecedented speed. This "situational awareness" could be the difference between a contained cluster of infections and a community-wide epidemic.
3. Economic Accessibility
By utilizing a lower-cost instrument and consumable model, Co-Diagnostics is targeting the economic barriers that have traditionally kept molecular testing out of smaller clinics and rural health centers. If successful, this could reduce the overall burden on the US healthcare system by preventing unnecessary hospitalizations and reducing the overuse of antibiotics in cases where the pathogen is viral rather than bacterial.
4. Regulatory Precedent
The success of this application will set a new bar for how the FDA evaluates decentralized molecular platforms. If the CLIA Waiver is granted, it could pave the way for a broader suite of diagnostic tests on the Co-Dx platform, potentially expanding into other areas of infectious disease and beyond, including chronic disease monitoring and genetic marker identification.
Conclusion: A Future-Forward Outlook
As the FDA begins its review of the Co-Dx PCR platform, the diagnostics industry watches with keen interest. The transition from centralized laboratory reliance to decentralized, patient-centric molecular testing is an inevitable evolution, but one that requires both technological innovation and stringent regulatory scrutiny.
Co-Diagnostics has positioned itself at the vanguard of this transition. While the platform—including the PCR Home and PCR Pro instruments—remains subject to final regulatory clearance, the sheer scope of the clinical data and the strategic design of the system suggest a company that has done its due diligence. Should the FDA grant the requested clearances, the Co-Dx platform could become a permanent fixture in the modern clinical environment, fundamentally changing how we diagnose, treat, and track respiratory illnesses in the 21st century.
As it stands, the company remains in a "pre-market" state, with all eyes on the regulatory horizon. The next twelve months are expected to be the most transformative in Co-Diagnostics’ history, as they look to transition from a developer of diagnostic technology to a provider of national-scale health infrastructure.
About the Author
